Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
Sponsor: Ichnos Sciences SA
This PHASE1 trial investigates Relapsed/Refractory Multiple Myeloma and is currently actively recruiting participants. Ichnos Sciences SA leads this study, which shows 9 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE1
-
Oct 2025 — Mar 2026 [monthly]
Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Jul 2025 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ichnos Sciences SA
For direct contact, visit the study record on ClinicalTrials.gov .